Trial Profile
NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NAXIVA
- 23 Jun 2022 Results published in the British Journal of Cancer
- 19 Feb 2022 Results of a translational analysis presented at the 2022 Genitourinary Cancers Symposium
- 13 Sep 2021 Results translational studies examining the role of the tumor microenvironment (TME) and response to axitinib presented at the 116th Annual Meeting of the American Urological Association